• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Ozempic Reduces Kidney Disease Progression, Cardiovascular Events by 24%

News
Article

The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.

In patients with type 2 diabetes and kidney disease, Ozempic (semaglutide) reduced kidney disease progression, major adverse cardiovascular events (MACE) and death by 24%, according to topline results from the FLOW trial. The trial was stopped early on the recommendation from an independent data monitoring committee because an interim analysis found the study met the criteria for efficacy.

In the trial, which enrolled 3,533 people with type 2 diabetes and chronic kidney disease, patients were randomized to receive Ozempic 1.0 mg with placebo or placebo, along with standard of care for kidney disease.

Secondary endpoints — including annual rate of change in eGFR1 and non-fatal myocardial infarction, non-fatal stroke, cardiovascular death — also confirmed the positive impact on slowing kidney disease and cardiovascular events. 

Ozempic, which was developed by Novo Nordisk, is available in 0.5 mg, 1.0 mg and 2.0 mg doses. It is a glucagon-like peptide-1 (GLP-1) inhibitor, a class of drugs that work in pancreas to enhance insulin release. The list price for Ozempic 1.0 mg is $935.77 for one pen.

A higher dose of semaglutide is also marketed as Wegovy with a weight loss indication. Wegovy has a list price of $1,349.02 per package, which is a 28-day supply.

Martin Holst Lange

Martin Holst Lange

“Approximately 40% of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease,” Martin Holst Lange, executive vice president for Development at Novo Nordisk, said in a press release.

Company officials said that full results will be presented at a conference this year.

Related: Wegovy Cuts Risk of Serious Cardiovascular Events By 20% in Those Without Diabetes, Study Finds | AHA Scientific Sessions

This follows the results of a separate trial, SELECT, announced last year. In that trial, the semaglutide product Wegovy 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults who were overweight who had obesity. The trial enrolled 17,604 adults aged 45 years or older with obesity and established cardiovascular disease with no prior history of diabetes. These results were released at the American Heart Association Scientific Session meeting in November 2023.

Novo Nordisk has filed for a label update of Wegovy in both the United States and the Europea Union based on the SELECT study findings, and a decision is expected in 2024

Related Videos
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Related Content
© 2024 MJH Life Sciences

All rights reserved.